Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Ian Karp - SVP, IR and Corporate Communications John Leonard - President and CEO David Lebwohl - EVP and CMO Laura Sepp-Lorenzino - EVP and CSO Glenn Goddard - EVP and Chief Financial Officer Eliana Clark - EVP and CTO Conference Call Participants Kostas Biliouris - BMO Capital Markets Joon Lee - Truist Securities Mani Forooher - Leerink Partners Unidentified Analyst - Guggenheim Partn ...

Intellia Therapeutics' Legal Disclaimer 3 Agenda Clinical Pipeline Updates Q3 Financials Summary 4 Agenda Dr. John Leonard Chief Executive Officer Glenn Goddard Chief Financial Officer | --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------|-----------------------------------------------------------|---------------------------------------------------|-----------------------------------------------------------------------|------------------------ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37766 INTELLIA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 36-4785571 (State or Other Jurisdict ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q2 2023 Earnings Conference Call August 3, 2023 8:00 AM ET Company Participants Ian Karp - SVP, IR and Corporate Communications John Leonard - President and CEO David Lebwohl - EVP and CMO Laura Sepp-Lorenzino - EVP and CSO Glenn Goddard - EVP and CFO Conference Call Participants Maury Raycroft - Jefferies Unidentified Analyst - RBC Capital Joseph Thome - TD Cowen Mary Kate - Bank of America Unidentified Analyst - Truist Securities Unidentified Analyst - Barclays De ...

Return to Appendix Table of Contents | --- | --- | |-------------|----------------------------------------------------------------------------------------------------------------------------------| | | | | Increasing | • Leveraging our technology while retaining rights to key areas of focus | | shareholder | • Accelerate development of programs outside key areas of focus | | value: | • Expand our pipeline with valuable rights in future commercial success • Access external expertise to enhance our platform | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37766 INTELLIA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 36-4785571 (State or Other Jurisdiction o ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Ian Karp - Senior Vice President, Investor Relations and Corporate Communications John Leonard - Chief Executive Officer David Lebwohl - Chief Medical Officer Laura Sepp-Lorenzino - Chief Scientific Officer Glenn Goddard - Chief Financial Officer Conference Call Participants Joseph Thome - TD Cowen Maury Raycroft - Jefferies Yanan Zhu - Wells Fargo Securities Dae Gon Ha - Stifel Liisa Bayko ...

l ■ l IIII Immuno-oncology Autoimmune diseases In Vivo Leader: First to Demonstrate Systemic CRISPR Gene Editing in Humans 12 * Lead development and commercial party; ** Rights to certain in vivo targets; *** Milestones & royalties only AATD: alpha-1 antitrypsin deficiency; CAR-T: chimeric Antigen Receptor T Cells; HSC: hematopoietic stem cells; OSC: ocular stem cells; TCR: T cell receptor Capable of delivering to multiple tissue types for various therapeutic applications | --- | --- | --- | --- | |-------| ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37766 INTELLIA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 36-4785571 (State or Other Jurisdiction ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2022 Results Conference Call February 23, 2023 8:00 AM ET Company Participants Ian Karp - Senior Vice President, Investor Relations and Corporate Communications John Leonard - Chief Executive Officer David Lebwohl - Chief Medical Officer Laura Sepp-Lorenzino - Chief Scientific Officer Glenn Goddard - Chief Financial Officer Conference Call Participants Maury Raycroft - Jeffries Greg Harrison - Bank of America Swapnil Malekar - Piper Sandler Terence Flynn - Morgan ...